A degradation fragment of type X collagen is a real-time marker for bone growth velocity

Ryan F. Coghlan, Jon A. Oberdorf, Susan Sienko, Michael D. Aiona, Bruce Boston, Kara Connelly, Chelsea Bahney, Jeremie LaRouche, Sarah M. Almubarak, Daniel T. Coleman, Irute Girkontaite, Klaus von der Mark, Gregory P. Lunstrum, William A. Horton

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite its importance as a key parameter of child health and development, growth velocity is difficult to determine in real time because skeletal growth is slow and clinical tools to accurately detect very small increments of growth do not exist. We report discovery of a marker for skeletal growth in infants and children. The intact trimeric noncollagenous 1 (NC1) domain of type X collagen, the marker we designated as CXM for Collagen X Marker, is a degradation by-product of endochondral ossification that is released into the circulation in proportion to overall growth plate activity. This marker corresponds to the rate of linear bone growth at time of measurement. Serum concentrations of CXM plotted against age show a pattern similar to well-established height growth velocity curves and correlate with height growth velocity calculated from incremental height measurements in this study. The CXM marker is stable once collected and can be accurately assayed in serum, plasma, and dried blood spots. CXM testing may be useful for monitoring growth in the pediatric population, especially responses of infants and children with genetic and acquired growth disorders to interventions that target the underlying growth disturbances. The utility of CXM may potentially extend to managing other conditions such as fracture healing, scoliosis, arthritis, or cancer.

Original languageEnglish (US)
Article numbereaan4669
JournalScience Translational Medicine
Volume9
Issue number419
DOIs
StatePublished - Dec 6 2017

Fingerprint

Bone Development
Collagen
Growth
Collagen Type X
Growth Disorders
Fracture Healing
Growth Plate
fibrinogen fragment X
Scoliosis
Child Development
Serum
Osteogenesis
Arthritis
Pediatrics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A degradation fragment of type X collagen is a real-time marker for bone growth velocity. / Coghlan, Ryan F.; Oberdorf, Jon A.; Sienko, Susan; Aiona, Michael D.; Boston, Bruce; Connelly, Kara; Bahney, Chelsea; LaRouche, Jeremie; Almubarak, Sarah M.; Coleman, Daniel T.; Girkontaite, Irute; Mark, Klaus von der; Lunstrum, Gregory P.; Horton, William A.

In: Science Translational Medicine, Vol. 9, No. 419, eaan4669, 06.12.2017.

Research output: Contribution to journalArticle

Coghlan, RF, Oberdorf, JA, Sienko, S, Aiona, MD, Boston, B, Connelly, K, Bahney, C, LaRouche, J, Almubarak, SM, Coleman, DT, Girkontaite, I, Mark, KVD, Lunstrum, GP & Horton, WA 2017, 'A degradation fragment of type X collagen is a real-time marker for bone growth velocity', Science Translational Medicine, vol. 9, no. 419, eaan4669. https://doi.org/10.1126/scitranslmed.aan4669
Coghlan, Ryan F. ; Oberdorf, Jon A. ; Sienko, Susan ; Aiona, Michael D. ; Boston, Bruce ; Connelly, Kara ; Bahney, Chelsea ; LaRouche, Jeremie ; Almubarak, Sarah M. ; Coleman, Daniel T. ; Girkontaite, Irute ; Mark, Klaus von der ; Lunstrum, Gregory P. ; Horton, William A. / A degradation fragment of type X collagen is a real-time marker for bone growth velocity. In: Science Translational Medicine. 2017 ; Vol. 9, No. 419.
@article{a1609c33d6dd4e92b2e9589d11f9ce94,
title = "A degradation fragment of type X collagen is a real-time marker for bone growth velocity",
abstract = "Despite its importance as a key parameter of child health and development, growth velocity is difficult to determine in real time because skeletal growth is slow and clinical tools to accurately detect very small increments of growth do not exist. We report discovery of a marker for skeletal growth in infants and children. The intact trimeric noncollagenous 1 (NC1) domain of type X collagen, the marker we designated as CXM for Collagen X Marker, is a degradation by-product of endochondral ossification that is released into the circulation in proportion to overall growth plate activity. This marker corresponds to the rate of linear bone growth at time of measurement. Serum concentrations of CXM plotted against age show a pattern similar to well-established height growth velocity curves and correlate with height growth velocity calculated from incremental height measurements in this study. The CXM marker is stable once collected and can be accurately assayed in serum, plasma, and dried blood spots. CXM testing may be useful for monitoring growth in the pediatric population, especially responses of infants and children with genetic and acquired growth disorders to interventions that target the underlying growth disturbances. The utility of CXM may potentially extend to managing other conditions such as fracture healing, scoliosis, arthritis, or cancer.",
author = "Coghlan, {Ryan F.} and Oberdorf, {Jon A.} and Susan Sienko and Aiona, {Michael D.} and Bruce Boston and Kara Connelly and Chelsea Bahney and Jeremie LaRouche and Almubarak, {Sarah M.} and Coleman, {Daniel T.} and Irute Girkontaite and Mark, {Klaus von der} and Lunstrum, {Gregory P.} and Horton, {William A.}",
year = "2017",
month = "12",
day = "6",
doi = "10.1126/scitranslmed.aan4669",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "419",

}

TY - JOUR

T1 - A degradation fragment of type X collagen is a real-time marker for bone growth velocity

AU - Coghlan, Ryan F.

AU - Oberdorf, Jon A.

AU - Sienko, Susan

AU - Aiona, Michael D.

AU - Boston, Bruce

AU - Connelly, Kara

AU - Bahney, Chelsea

AU - LaRouche, Jeremie

AU - Almubarak, Sarah M.

AU - Coleman, Daniel T.

AU - Girkontaite, Irute

AU - Mark, Klaus von der

AU - Lunstrum, Gregory P.

AU - Horton, William A.

PY - 2017/12/6

Y1 - 2017/12/6

N2 - Despite its importance as a key parameter of child health and development, growth velocity is difficult to determine in real time because skeletal growth is slow and clinical tools to accurately detect very small increments of growth do not exist. We report discovery of a marker for skeletal growth in infants and children. The intact trimeric noncollagenous 1 (NC1) domain of type X collagen, the marker we designated as CXM for Collagen X Marker, is a degradation by-product of endochondral ossification that is released into the circulation in proportion to overall growth plate activity. This marker corresponds to the rate of linear bone growth at time of measurement. Serum concentrations of CXM plotted against age show a pattern similar to well-established height growth velocity curves and correlate with height growth velocity calculated from incremental height measurements in this study. The CXM marker is stable once collected and can be accurately assayed in serum, plasma, and dried blood spots. CXM testing may be useful for monitoring growth in the pediatric population, especially responses of infants and children with genetic and acquired growth disorders to interventions that target the underlying growth disturbances. The utility of CXM may potentially extend to managing other conditions such as fracture healing, scoliosis, arthritis, or cancer.

AB - Despite its importance as a key parameter of child health and development, growth velocity is difficult to determine in real time because skeletal growth is slow and clinical tools to accurately detect very small increments of growth do not exist. We report discovery of a marker for skeletal growth in infants and children. The intact trimeric noncollagenous 1 (NC1) domain of type X collagen, the marker we designated as CXM for Collagen X Marker, is a degradation by-product of endochondral ossification that is released into the circulation in proportion to overall growth plate activity. This marker corresponds to the rate of linear bone growth at time of measurement. Serum concentrations of CXM plotted against age show a pattern similar to well-established height growth velocity curves and correlate with height growth velocity calculated from incremental height measurements in this study. The CXM marker is stable once collected and can be accurately assayed in serum, plasma, and dried blood spots. CXM testing may be useful for monitoring growth in the pediatric population, especially responses of infants and children with genetic and acquired growth disorders to interventions that target the underlying growth disturbances. The utility of CXM may potentially extend to managing other conditions such as fracture healing, scoliosis, arthritis, or cancer.

UR - http://www.scopus.com/inward/record.url?scp=85037335739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037335739&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aan4669

DO - 10.1126/scitranslmed.aan4669

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 419

M1 - eaan4669

ER -